GlassScriptPhysician profile
Tiffany E Polo
NPI 1548640873
$2,219.46
in general payments reported to CMS, 2019-2025
26 companies · $1,379 in 2025
The $1,379 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $238 · 2024: $602 · 2025: $1,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,201 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,200.61 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $317.58 | 2024-2025 | |
| Pfizer INC. | $228.27 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $220.02 | 2024-2025 | Airsupra, Tagrisso, Fasenra |
| Lilly USA, LLC | $199.88 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $191.49 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $157.58 | 2024-2025 | Glassia, Cuvitru, Trintellix |
| Glaxosmithkline, LLC. | $132.38 | 2024-2025 | Nucala |
| Boston Scientific Corporation | $119.58 | 2023 | Watchman Flx |
| Alkermes, INC. | $108.43 | 2025 | Lybalvi |
| Abbott Laboratories | $83.37 | 2023-2024 | Mitraclip, Freestyle Libre 3 |
| Electromed, INC. | $63.12 | 2024-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.84 | 2024-2025 | Jardiance, Tradjenta |
| United Therapeutics Corporation | $42.56 | 2025 | Tyvaso |
| Abiomed | $37.89 | 2024-2025 | Impella |
| Philips North America LLC | $32.41 | 2025 | Vest Therapy Und |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $31.47 | 2025 | Rezzayo |
| Actelion Pharmaceuticals US, INC. | $31.41 | 2024 | Uptravi |
| Bard Peripheral Vascular, INC. | $26.77 | 2025 | Peritx |
| Hologic Sales and Service, LLC | $22.84 | 2025 | Aptima |
| Mylan Specialty L.P. | $22.21 | 2024 | Yupelri |
| Viatris Specialty LLC | $19.36 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $18.82 | 2025 | Auvelity |
| Genzyme Corporation | $16.95 | 2025 | |
| Paratek Pharmaceuticals, INC. | $14.64 | 2024 | Nuzyra |
| Amgen INC. | $14.23 | 2025 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $13.36 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Polo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.